Safety issues related to intravenous contrast agent use in magnetic resonance imaging

Skorn Ponrartana; Michael M. Moore; Sherwin S. Chan; Teresa Victoria; Jonathan R. Dillman; Govind B. Chavhan

doi:10.1007/s00247-020-04896-7

Safety issues related to intravenous contrast agent use in magnetic resonance imaging

Skorn Ponrartana, Michael M. Moore, Sherwin S. Chan, Teresa Victoria, Jonathan R. Dillman, Govind B. Chavhan

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

Gadolinium-based contrast agents (GBCAs) have been used to improve image quality of MRI examinations for decades and have an excellent overall safety record. However, there are well-documented risks associated with GBCAs and our understanding and management of these risks continue to evolve. The purpose of this review is to discuss the safety of GBCAs used in MRI in adult and pediatric populations. We focus particular attention on acute adverse reactions, nephrogenic systemic fibrosis and gadolinium deposition. We also discuss the non-GBCA MRI contrast agent ferumoxytol, which is increasing in use and has its own risk profile. Finally, we identify special populations at higher risk of harm from GBCA administration.

Original language	English (US)
Pages (from-to)	736-747
Number of pages	12
Journal	Pediatric Radiology
Volume	51
Issue number	5
DOIs	https://doi.org/10.1007/s00247-020-04896-7
State	Published - May 2021

All Science Journal Classification (ASJC) codes

Pediatrics, Perinatology, and Child Health
Radiology Nuclear Medicine and imaging

Access to Document

10.1007/s00247-020-04896-7

Cite this

@article{190621aa2f8e42bea19f14f84a5fb5d7,

title = "Safety issues related to intravenous contrast agent use in magnetic resonance imaging",

abstract = "Gadolinium-based contrast agents (GBCAs) have been used to improve image quality of MRI examinations for decades and have an excellent overall safety record. However, there are well-documented risks associated with GBCAs and our understanding and management of these risks continue to evolve. The purpose of this review is to discuss the safety of GBCAs used in MRI in adult and pediatric populations. We focus particular attention on acute adverse reactions, nephrogenic systemic fibrosis and gadolinium deposition. We also discuss the non-GBCA MRI contrast agent ferumoxytol, which is increasing in use and has its own risk profile. Finally, we identify special populations at higher risk of harm from GBCA administration.",

author = "Skorn Ponrartana and Moore, {Michael M.} and Chan, {Sherwin S.} and Teresa Victoria and Dillman, {Jonathan R.} and Chavhan, {Govind B.}",

note = "Publisher Copyright: {\textcopyright} 2021, Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2021",

month = may,

doi = "10.1007/s00247-020-04896-7",

language = "English (US)",

volume = "51",

pages = "736--747",

journal = "Pediatric Radiology",

issn = "0301-0449",

publisher = "Springer Nature",

number = "5",

}

TY - JOUR

T1 - Safety issues related to intravenous contrast agent use in magnetic resonance imaging

AU - Ponrartana, Skorn

AU - Moore, Michael M.

AU - Chan, Sherwin S.

AU - Victoria, Teresa

AU - Dillman, Jonathan R.

AU - Chavhan, Govind B.

PY - 2021/5

Y1 - 2021/5

N2 - Gadolinium-based contrast agents (GBCAs) have been used to improve image quality of MRI examinations for decades and have an excellent overall safety record. However, there are well-documented risks associated with GBCAs and our understanding and management of these risks continue to evolve. The purpose of this review is to discuss the safety of GBCAs used in MRI in adult and pediatric populations. We focus particular attention on acute adverse reactions, nephrogenic systemic fibrosis and gadolinium deposition. We also discuss the non-GBCA MRI contrast agent ferumoxytol, which is increasing in use and has its own risk profile. Finally, we identify special populations at higher risk of harm from GBCA administration.

AB - Gadolinium-based contrast agents (GBCAs) have been used to improve image quality of MRI examinations for decades and have an excellent overall safety record. However, there are well-documented risks associated with GBCAs and our understanding and management of these risks continue to evolve. The purpose of this review is to discuss the safety of GBCAs used in MRI in adult and pediatric populations. We focus particular attention on acute adverse reactions, nephrogenic systemic fibrosis and gadolinium deposition. We also discuss the non-GBCA MRI contrast agent ferumoxytol, which is increasing in use and has its own risk profile. Finally, we identify special populations at higher risk of harm from GBCA administration.

UR - http://www.scopus.com/inward/record.url?scp=85104745084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104745084&partnerID=8YFLogxK

U2 - 10.1007/s00247-020-04896-7

DO - 10.1007/s00247-020-04896-7

M3 - Review article

C2 - 33871726

AN - SCOPUS:85104745084

SN - 0301-0449

VL - 51

SP - 736

EP - 747

JO - Pediatric Radiology

JF - Pediatric Radiology

IS - 5

ER -

Safety issues related to intravenous contrast agent use in magnetic resonance imaging

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this